Molecular reference laboratory Symbiodx, located in the Pacific Northwest, has partnered with multi-sided technology platform Cure Forward to enhance precision medicine; the new collaboration will make it possible for patients to have easier access to their genomic data, meaning there will exist a greater chance for them to be involved in relevant clinical trials, as part of Symbiodx's goal to provide next generation sequencing (NGS) assay for cancer.
"Symbiodx pathologists and staff are involved with the diagnosis and care of more than 10,000 cancer patients per year," said Anna Berry, M.D., director of molecular pathology at Symbiodx. "We are very proud of the quality and service we provide to our patients and their treating physicians. Partnering with Cure Forward will allow us to provide an additional service to our cancer patients in helping them connect with clinical trials.”
Using Cure Forward’s website, patients can retrieve molecular diagnostic test results ordered by their physicians from accredited laboratory test providers, then use that data to find educational information, network with other patients and research treatment options -- such as clinical trials.
“Bringing audiences together online is a type of innovation that has helped solve so many of life’s problems, from finding a ride to funding a startup," Cure Forward CEO Martin Naley said.
For more information about Symbiodx, visit www.symbiodx.com, and for more information about Cure Forward, visit www.CureForward.com.
